EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY

Confinia Cephalalgica · 03.11.2026 · 36 (s1)

DOI: 10.4081/cc.2026.15988 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Confinia Cephalalgica, online erschienen am 03.11.2026. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Depression and anxiety disorders are common migraine comorbidities contributing substantially to disease burden. Whether mood improvement during anti-calcitonin gene related peptide pathway treatments is entirely attributable to reductions in headache frequency remains unclear. We evaluated longitudinal changes in self-reported depressive and anxiety symptoms during eptinezumab treatment and their relationship with clinical outcomes.

Methods

This post-hoc analysis of the TACHIS study, a prospective, multicenter, real-world study, included patients with episodic or chronic migraine who started eptinezumab across 23 Italian headache centers. Depressive and anxiety symptoms were assessed at baseline and after 12 and 24 weeks using the validated Hamilton Depression Rating Scale (HAM-D) and Hamilton Anxiety Rating Scale (HAM-A). Migraine outcomes included monthly headache days (MHDs), acute medication days (AMDs), the Migraine Disability Assessment (MIDAS), the Headache Impact Test-6 (HIT-6) and the Migraine-Specific Quality of Life Questionnaire (MSQ). Longitudinal changes were evaluated using mixed-effects models adjusted for demographic and clinical covariates.

Results

A total of 128 patients were included (82.0% female; mean age 46.9±12.4 years). 24 patients (18.8%) had pre-existing psychiatric comorbidities, including depression, anxiety, personality disorders, and bipolar disorder. Linear mixed-effects models demonstrated significant reduction in MHDs and AMDs, migraine-related disability (MIDAS and HIT-6 questionnaires), and migraine-specific quality of life (MSQ) during eptinezumab treatment (all p

Zitieren

APA

(2026). P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY. Confinia Cephalalgica, 36(s1). https://doi.org/10.4081/cc.2026.15988

Vancouver

P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY. Confinia Cephalalgica. 2026;36(s1). doi:10.4081/cc.2026.15988

BibTeX
@article{euvimed2026,
  title = {P032 | IMPROVEMENT IN DEPRESSIVE AND ANXIETY SYMPTOMS DURING EPTINEZUMAB TREATMENT: A POST-HOC ANALYSIS FROM THE TACHIS STUDY},
  journal = {Confinia Cephalalgica},
  year = {2026},
  volume = {36},
  number = {s1},
  doi = {10.4081/cc.2026.15988}
}
Kostenlos starten →